Mucosal Kaposi sarcoma, a rare cancer network study

Juliette Thariat, Youlia Kirova, Terence Sio, Olivier Choussy, Hans Vees, Ulrich Schick, Gilles Poissonnet, Esma Saada, Antoine Thyss, Robert C. Miller

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Kaposi's sarcoma (KS) most often affect the skin but occasionally affect the mucosa of different anatomic sites. The management of mucosal KS is seldom described in the literature. Data from 15 eligible patients with mucosal KS treated between 1994 and 2008 in five institutions within three countries of the Rare Cancer Network group were collected. The inclusion criteria were as follows: age >16 years, confirmed pathological diagnosis, mucosal stages I and II, and a minimum of 6 months' follow-up after treatment. Head and neck sites were the most common (66%). Eleven cases were HIV-positive. CD4 counts correlated with disease stage. Twelve patients had biopsy only while three patients underwent local resection. Radiotherapy (RT) was delivered whatever their CD4 status was. Median total radiation dose was 16.2 Gy (0-45) delivered in median 17 days (0-40) with four patients receiving no RT. Six patients underwent chemotherapy and received from 1 to 11 cycles of various regimens namely vinblastin, caelyx, bleomycine, or interferon, whatever their CD4 counts was. Five-year disease free survival were 81.6% and 75.0% in patients undergoing RT or not, respectively. Median survival was 66.9 months. Radiation-induced toxicity was at worse grade 1-2 and was manageable whatever patients' HIV status. This small series of mucosal KSs revealed that relatively low-dose RT is overall safe and efficient in HIV-positive and negative patients. Since control was calculated from the date of diagnosis to the date of local recurrence. Survival curves were constructed using the Kaplan- Meier method and differences were considered significant if the P value was <0.05 (twotailed log rank test).

Original languageEnglish (US)
Pages (from-to)156-161
Number of pages6
JournalRare Tumors
Volume4
Issue number4
DOIs
StatePublished - 2012

Keywords

  • Classic
  • HIV
  • Head and neck
  • Kaposi sarcoma
  • Mucosal
  • Radiation therapy
  • Systemic treatment

ASJC Scopus subject areas

  • Histology
  • Oncology

Fingerprint Dive into the research topics of 'Mucosal Kaposi sarcoma, a rare cancer network study'. Together they form a unique fingerprint.

  • Cite this

    Thariat, J., Kirova, Y., Sio, T., Choussy, O., Vees, H., Schick, U., Poissonnet, G., Saada, E., Thyss, A., & Miller, R. C. (2012). Mucosal Kaposi sarcoma, a rare cancer network study. Rare Tumors, 4(4), 156-161. https://doi.org/10.4081/rt.2012.e49